Could a single injection replace biopsies for breast cancer?

NCT ID NCT07292571

ENROLLING_BY_INVITATION Diagnosis Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial is testing a new imaging agent called [99mTc]Tc-ZHER2:4107 to see how well it can detect different levels of HER2 protein in breast cancer tumors. Fifty participants will receive one injection followed by a SPECT/CT scan. The goal is to improve diagnosis and help doctors choose the right treatment without needing a tissue biopsy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Technetium-99m-labelled affibody [99mTc]Tc-ZHER2:4107
What this could lead to: If successful, this imaging method could help doctors better identify HER2 status in breast cancer without needing a biopsy, guiding more personalized treatment.
What could go wrong: This is a small early-phase trial with only 50 participants, so results may not apply to all patients. The imaging agent's accuracy and safety are still being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY BREAST CANCER

Contacts and locations

Locations

Cancer Research Institute of Tomsk National Research Medical Center of the Russian Academy of Sciences

Tomsk, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.